Author name: Leonardo Arias

The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.

When Roche previewed the Axelios technology in February, a Jefferies analyst called the next-generation sequencing platform the “greatest credible competitive threat in years.”

Pacira’s iovera device uses cold therapy for targeted pain relief. An analyst said the addition complements Zimmer Biomet’s portfolio.

Investment firm Deerfield Management is the latest to find a gem in China, which has been rising as a source of biotech innovation over the past few years.

Vijay Kumar, acting director of CBER’s Office of Therapeutic Products, will leave his role at a tumultuous time for the FDA.

At the BIO International Convention in San Diego, attendees marked the 50th anniversary of original biotech Genentech, reflecting on the immense challenges facing companies as China becomes a powerhouse innovator.

Unicycive Therapeutics and Sobi received complete response letters for kidney disease and gout filings, respectively, after the FDA found fault with their manufacturing partners.

Who is the highest paid CEO in all of pharma? In this special edition, BioSpace examines top paid CEOs and their pay packages.

Christina Zamarro will take over the role in July after spending nearly 20 years at Goodyear Tire & Rubber Company, most recently serving as its CFO.  

En 1985, se descubrió un agujero en la capa estratosférica de ozono que protege a la Tierra de radiaciones malignas provenientes del espacio. Ese agujero estaba situado encima de la Antártida. El agujero era la manifestación más elocuente de un grave agotamiento de …